{"schema_version":"secwatch.filing_event.v1","accession":"0001522767-26-000027","form_type":"8-K","ticker":"MRMD","cik":"0001522767","company_name":"MARIMED INC.","filed_at":"2026-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.316553+00:00","generated_at":"2026-05-15T14:46:12.600365+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MariMed reports FY2025 revenue of $159.8M, net loss widens to $14.5M, adjusted EBITDA down to $16.9M","bullets":["FY2025 revenue $159.8M, up from $157.7M in FY2024; Q4 revenue $41.7M vs $38.9M.","GAAP net loss $14.5M in FY2025 vs $12.4M; Non-GAAP adjusted EBITDA $16.9M, down from $19.3M.","Wholesale revenue increased 11%; distribution reached 85% of dispensaries in core markets.","Betty's Eddies ranked #1 edible in MA, MD, DE, IL; restructured Series B debt, extending maturity 4.6 years.","CEO cites growth drivers for 2026: Delaware adult-use, Maine brand licensing, new Columbus OH dispensary."],"urls":{"canonical":"https://secwatch.observer/filing/0001522767-26-000027","json":"https://secwatch.observer/filing/0001522767-26-000027.json","markdown":"https://secwatch.observer/filing/0001522767-26-000027.md","text":"https://secwatch.observer/filing/0001522767-26-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1522767/000152276726000027/0001522767-26-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1522767/000152276726000027/mrmd-20260311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T14:46:12.600365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}